Breast Invasive Ductal Carcinoma (IDC): Triple-negative (basal-like)

Chemo-intensive with immunotherapy in high-risk early disease; ADCs and PARP inhibitors (gBRCA) in metastatic settings.

• ER–/PR–/HER2–
• PD-L1 CPS subset positive

• DNA damage repair defects (gBRCA)
• Immune-inflamed microenvironment subset

• Higher early relapse risk; brain and visceral metastases.
• Need for pCR-oriented neoadjuvant therapy and adjuvant adaptation.

• Baseline staging for stage II–III; brain MRI if neuro symptoms.

• Back to Breast Invasive Ductal Carcinoma (IDC) overview
• Breast Invasive Ductal Carcinoma (IDC): Luminal A–like
• Breast Invasive Ductal Carcinoma (IDC): Luminal B–like
• Breast Invasive Ductal Carcinoma (IDC): HER2-enriched